Director and Senior Scientist
Tier 1 Canada Research Chair in Human Stem Cell Biology
Michael G. DeGroote Chair in Stem Cell and Cancer Biology
Location: MDCL 5020
“I’m moved by the notion that in cancer, your own cells are turning on you. I want to understand how that starts and how we can stop it.”
At the core of Dr. Bhatia’s research program is how human cells identify changes. In studying both normal and cancerous [Acute Myeloid Leukemia (AML)] development in the human blood system, the Bhatia lab seeks to understand why this disease occurs and how to stop it. The program is focused on understanding the molecular processes (signalling, epigenetics and transcriptional changes) that govern somatic and pluripotent human stem cell development.
Throughout his research career, Dr. Bhatia has been pursuing this question from numerous angles and using a variety of model systems. These include the use of embryonic stem cells, induced pluripotent stem cells (iPSCs), and most recently through the SCC-RI drug discovery screening platform.
An important component of the program is drug screening in the David Braley Human Stem Cell Screening Facility. The drug discovery screening activity is focused on identifying anti-cancer hits for cancers including AML, breast, colon and brain. Beyond cancer, the cell screening platform is also being adapted for other diseases including chemotherapy-induced peripheral neuropathy (CIPN), autism and neuropathic pain.
Recently, Dr. Bhatia’s research program has shifted to a greater emphasis on translational, clinical studies. The goal of this translational work is to positively affect human health, and test new ideas and therapeutics for patients whose options are currently limited by standard care. To this end, there are numerous ongoing pre-clinical and clinical activities, including a Phase I clinical trial and collaborations with the private sector to support parallel communications that ultimately supports clinical testing.
To develop cell-based tools for use in drug screening of patient-specific stem cells.
To identify novel therapeutics that can target the bone marrow environment to destroy and prevent leukemia. By better understanding the optimal bone marrow conditions needed to support healthy blood stem cells, this study also has the potential to improve stem cell transplantation therapies.
The combination of standard of care chemotherapy, coupled with novel drugs discovered by our group, is hoped to prevent cancer relapse.
The ability to screen for drugs that can target the root causes of neural disorders, including pain and dysfunction in autism spectrum disorder.
The potential to introduce a new therapeutic for AML, a disease which has not seen therapeutic progress in decades.
|Rouknuddin Ali||Post-Doctoral Fellowemail@example.com|
|Mohammed Almakadi||Graduate Studentfirstname.lastname@example.org|
|Lili Aslostovar||Graduate Studentemail@example.com|
|Yannick Benoit||Post-Doctoral Fellowfirstname.lastname@example.org|
|Allison Boyd||Post-Doctoral Fellowemail@example.com|
|Juan Luis Garcia-Rodriguez||Post-Doctoral Fellowfirstname.lastname@example.org|
|Saleemulla Mahammad||Post-Doctoral Fellowemail@example.com|
|Marie-Pierre Mathieu||Technical Stafffirstname.lastname@example.org|
|Ryan Mitchell||Post-Doctoral Fellowemail@example.com|
|Mio Nakanishi||Post-Doctoral Fellowfirstname.lastname@example.org|
|Luca Orlando||Post-Doctoral Fellowemail@example.com|
|Deanna Porras||Graduate Studentfirstname.lastname@example.org|
|Jennifer Reid||Graduate Studentemail@example.com|
|Jennifer Russell||Technical Stafffirstname.lastname@example.org|
|Borko Tanasijevic||Post-Doctoral Fellowemail@example.com|
|Wendy Ye||Graduate Studentfirstname.lastname@example.org|
Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells.
Cell. 2012 June 8; 149(6):1284-97.
Single transcription factor conversion of human blood fate to NPCs with CNS and PNS developmental capacity.
Cell Reports. 2015 Jun 9; 11(9): 1367-76.
Cell Stem Cell. 2013 Aug 1; 13(2):175-89.